Morocco, Poland and Vietnam Earmarked for Pharma Growth
- Three growth hotspots identified for ambitious pharma businesses and specialist consultants
- Drivers include rapid population growth, a burgeoning ‘middle-class’ and healthcare reforms
- Enquiries for support on pharma projects on the rise
As we see demand for support on pharma projects rise, we’ve identified three growth hotspots that ambitious businesses and specialist consultants in the pharma sector should keep a watchful eye on:
|The Moroccan government has highlighted pharma as one of the industries that will boost its economy as part of its Industrial Acceleration Plan. The plan sets out measures to develop Morocco’s pharma industrial base and export capabilities by forming partnerships with other African nations. This will help the country to become a pharma hub for companies keen to serve Africa with the creation of a direct export platform to reach the rest of the continent.|
|There are a range of legal changes on the horizon in Poland where specialist pharmaceutical and healthcare experience could be in demand. These include a planned programme of free drugs and medical devices for persons aged over 75 years; a mandatory vaccination against pneumococcal disease; and the launch of Poland’s National Plan for Rare Diseases.|
Figures from BMI Research show the Vietnamese pharma market is expected to grow from US$4.2bn to $7.2 billion by 2020. However, there are some hurdles to overcome for the sector where experience and expertise will be at a premium.
These include regulatory issues, such as inadequate intellectual property regimes and the underlying problem of corruption among healthcare officials. There is also a significant variation in pricing across the country which needs to be tackled to create a more stable market.
The common themes in the development of these markets centre around rapid population growth, a burgeoning ‘middle-class’ and healthcare reforms, underpinned by investment in their domestic pharma industries which is expected to continue well into 2017 and beyond.
Despite growth in the pharmaceutical industry being driven by the usual suspects, including those that make up the BRIC countries (Brazil, Russia, India and China), it is these less obvious markets where we see the most potential for businesses looking for somewhere to invest.
With big pharma companies like Novartis, Sanofi and Astra Zeneca all investing in emerging markets through acquisition or local partnerships, we are also seeing an increasing need for specialist consultants and project teams who can apply best practice from other markets to create consistently high standards. As well as medical and scientific roles, there is a demand for expertise in supporting roles including legal, technical and financial posts.
We work with clients to manage the life cycle of pharmaceutical projects across the globe, helping them source talent, mobilise new and existing teams and navigate the international legal, political and financial landscape. We also support businesses through on-site project management and end of project reporting, ensuring that the full project life cycle is complete.
To see how we can support your business please visit our client page here.